MIAX Emerald Regulatory Circular 2019-46 DATE
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Printmgr File
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 The Greenbrier Companies, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: One Centerpointe Drive Suite 200 Lake Oswego, Oregon 97035 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS January 7, 2016 To Our Shareholders: The Annual Meeting of Shareholders of The Greenbrier Companies, Inc. -
2015 Annual Report We’Re Committed to Advancing the Field of Conservation and Fixing Freshwater at a Pace and Scale That Matters for Today and Tomorrow
2015 Annual Report We’re committed to advancing the field of conservation and fixing freshwater at a pace and scale that matters for today and tomorrow. We’re FRIENDS, committed When I think about where The Freshwater Trust was ten, five and even one year ago, I’m astounded by our growth, perseverance and tenacity. These qualities don’t just to advancing appear. They take time to cultivate. They come from having the field of people like you behind us. That’s why I know I speak for the entire staff when I say thank you for your dedication and investment in 2015. It’s made a conservation real difference in the impact The Freshwater Trust has made on the world of conservation. With a solid foundation, we have and fixing the confidence to jump for the big solutions. This is what you want out of any good organization. Deep roots. Strategic freshwater at ambition. Relentless effort. Our donors have helped The Freshwater Trust grow to nearly 50 staff members with four offices in three states — including a pace and the new headquarters in downtown Portland. Over the last year, we’ve taken our tools and technologies to the next scale that level. We gained traction with more cities, farmers, ranchers, conservation groups and the public at large. We owe success like this to you. Rest assured: We will continue fighting for matters outcomes that matter and bring our innovative solutions to bear on the most pressing problems in Oregon, California, for today and Idaho and the country at large. -
Advancing Cell Therapeutic Products for Clinical Use
Advancing cell therapeutic products for clinical use 1 Proprietary data of Pluristem Therapeutics Inc. Forward Looking Statement This presentation concerning Pluristem Therapeutics may include forward- looking statements which represent Pluristem Therapeutics' expectations or beliefs regarding future events. I caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in Pluristem Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. Pluristem Therapeutics assumes no obligation to update these forward- looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements. www.pluristem.com 2 Proprietary data of Pluristem Therapeutics Inc. Corporate Overview • Cell therapy company (NasdaqCM: PSTI, TASE: PSTI) • Using off-the-shelf, placenta-derived cells to achieve both local and systemic therapeutic effects – no tissue matching needed • First-in-class 3D cell culturing technology allowing for efficient, controlled production of multiple cell products in commercial quantities – “the process is the product” • Active with regulators in the U.S., EU, S. Korea, Australia & Israel • Demonstrated safety and efficacy in 3 clinical studies (two Phase I and one Phase I/II study) 3 Proprietary data of Pluristem Therapeutics Inc. Financial Overview • Market Cap: ~ $200 million • Cash and marketable securities: $41 million (March, 2015) • No debt • Net burn: ~ $23 million • 165 employees (16 PhD, 4 MD) • IP Ownership: over 40 granted patents and ~150 pending applications 4 Proprietary data of Pluristem Therapeutics Inc. -
509 22,233 51%
METALS & MACHINERY Benchmade A Manufacturing Powerhouse Greater Portland is home to firms that manufacture highly specialized products, including Freightliners from Daimler Trucks, passenger ferries and cargo ships at Vigor Industrial, and aerospace parts from Boeing. Other Portland-area firms include Schnitzer Steel and Precision Castparts. The region’s metals and machinery sector is outperforming its national peers in job growth by 10 percent. INDUSTRY SNAPSHOT 509 Total number of establishments 22,233 Total employment in metals and machinery industries 51% Manufacturers in Oregon account for 22%, or Employment growth versus $49.4 billion, of the state’s total economic output. the national average TOP METALS + MACHINERY FIRMS IN GREATER PORTLAND 10% Job growth outperforming Precision Castparts Vigor Industrial Leatherman Tool national peers in metals and Corp. 1,230 employees Group machinery sector. 3,849 employees 503 employees Greenbrier Schnitzer Steel 1,103 employees EVRAZ North 3,183 employees America A-dec 450 employees Daimler Trucks North 1,100 employees America Blount International 3,000 employees 527 employees The Boeing Company 1,500 employees —PBJ Book of Lists, 2019 SUCCESS STORIES BOEING OREGON MANUFACTURING The aerospace company employs over 1,500 at its plant INNOVATION CENTER in Gresham, where it makes parts for its jets. These parts The Oregon Manufacturing Innovation Center (OMIC) include a component used to extend and retract wing is a partnership between industry leaders, research flaps during flight. This is Boeing’s largest machine shop institutions and local agencies that provides advanced and provides components to every Boeing aircraft. technical training for the region’s workforce while developing new tools, techniques and technologies that PRECISION CASTPARTS address real-world manufacturing challenges facing the Founded in 1953, Portland-based Precision Castparts industry. -
Biolinerx Ltd. (Translation of Registrant’S Name Into English) ______
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 _______________________ BioLineRx Ltd. (Translation of registrant’s name into English) _______________________ 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) _______________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☑ Form 40-F ☐ Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: Yes ☐ No ☑ The registrant hereby announces that it has entered into an employment agreement with Hillit Mannor Shachar, M.D., MBA, M.S.F.S., to serve as its new Vice President Business Development, effective April 1, 2018. Dr. Shachar will be responsible for BioLineRx’s business development, commercialization of assets and pipeline strategy. Dr. Shachar joins BioLineRx with over 15 years of experience in senior business development, corporate development and venture capital positions in the life sciences field. Her recent experience has included service as Vice President Business Development of Pluristem Therapeutics (NASDAQ:PSTI), a leading developer of placenta-based cell therapy products, and Director of New Business Development at West Pharmacuetical Services. In addition, Dr. Shachar has served at several life science companies and venture capital funds, including Apax Partners, Nektar Therapeutics, Orex Computed Radiography, Kodak and Transpharma Medical. -
PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant As Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 98-0351734 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) MATAM Advanced Technology Park, Building No. 5, Haifa, Israel 31905 (Address of principal executive offices) (Zip Code) Registrant's telephone number 011-972-74-7107259 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, par value $0.00001 Nasdaq Capital Market Securities registered pursuant to Section 12(g) of the Act: None. (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. -
2014 Economic Impacts of Congestion
PHOTOS COURTESY OF PORT OF PORTLAND OF PORT OF COURTESY PHOTOS ECONOMIC IMPACTS OF CONGESTION 2014 on the Portland-metro and Oregon economy About this report In 2005, the Portland Business Alliance, Port of As we have learned through other research, our available from four metropolitan planning Portland, Oregon Department of Transportation, region and state are uniquely trade dependent. organizations around the state, including Portland, METRO, and several other public and private Between 2004 and 2011, Oregon’s trade-related mid-Willamette Valley, Bend and Corvallis, were sector partners completed a groundbreaking study employment grew 7.5 times faster than total used to show the results. titled, “The Cost of Congestion to the Economy employment. In addition, about 90 percent of of the Portland Region.” The study provided key Oregon exporters are small- to medium-sized The study seeks to answer the following questions: information about the importance of investing in businesses. Today, it remains critical to our What are the impacts of highway our transportation system, particularly roads and economy and our quality of life that we adequately congestion on the economic performance highways, as a critical part of our economy. invest in improvements that ensure an efficient and of Oregon and major metropolitan areas of reliable transportation system. The study concluded that geography and past the state? investments have made Portland-metro a sea This 2014 study provides a better understanding of How has congestion affected business and air gateway as well as a regional rail and how congestion and transportation barriers affect transportation decisions and operations in highway hub. -
Life Sciences in Israel
STATE OF ISRAEL Ministry of Industry Trade and Labor Investment Promotion Center Inspiration Invention Innovation Life Sciences in Israel www.investinisrael.gov.il Table of Contents .......................................... 3 Israel: A Powerhouse of Opportunities ............................................................ 3 Israel’s Life Science Sectors Medical Devices ........................................................................ 4 Healthcare IT ............................................................................ 4 BioPharmaceutical .................................................................... 7 Israel’s Biomedical Engineering - ................................................... 11 Spotlight on Stem Cell Research ....................................... 15 Israel’s Life Sciences Competitive Edge ..................................................................... 19 Government Support 2 Life Sciences in Israel Israel: A Powerhouse of Opportunities Why Israel’s Life Sciences Over the last decade, Israel has introduced a wealth of groundbreaking More than 1,000 Life and valuable innovations in Life Sciences. Israel’s Life Sciences sector Sciences Companies - is supported by a strong foundation of academic excellence, including Biopharma and Medical some of the world’s leading research institutes, renowned R&D Devices facilities and cutting-edge medical centers. Bolstered by a highly skilled Over 1/3 of LS Start-Ups workforce, a flourishing high-tech environment, and an entrepreneurial already generate revenue -
Associated Oregon Industries Re: Overtime Reform and Enhancement Act July 19, 2016 July 19, 2016 Page 2
Letter to Representative Kurt Schrader From Betsy Earls, Associated Oregon Industries Re: Overtime Reform and Enhancement Act July 19, 2016 July 19, 2016 Page 2 The Honorable Kurt Schrader U.S. House of Representatives 2431 Rayburn House Office Building Washington, D.C. 20515 Subject: Overtime Reform and Enhancement Act Dear Representative Schrader: OFFICERS Chairman of the Board I am writing to express Associated Oregon Industries’ strong support for the Overtime Reform R. PATRICK REITEN PacifiCorp Transmission and Enhancement Act. AOI appreciates your leadership on this issue of critical importance to President & CEO the business community. JAY M. CLEMENS Associated Oregon Industries First Vice-Chair The new overtime regulations present a variety of troubling issues that impact all Oregonians, SCOTT N. PARRISH A-dec, Inc. from workers to consumers to employers. As a predominantly small business state with a Treasurer significant rural population, Oregon bears a disproportionately heavy burden relative to other THOMAS J. CORRY Bank of America Merrill Lynch states. Immediate Past Chair NEIL J. NELSON Siltronic Corporation Oregon’s unique economy The recently-imposed overtime rules ignore the variation in individual states’ economies and typical salaries. The cost of living—and, therefore, the wage required to maintain that EXECUTIVE COMMITTEE standard of living—varies widely by state and region. According to data from the U.S. Bureau JON E. BLADINE Oregon Lithoprint, Inc. of Economic Analysis, in 2013 Oregonians paid less to live in Oregon than their counterparts CARMEN M. CALZACORTA across the U.S. Schwabe, Williamson & Wyatt, PC ROBERT T. FRERES, JR. Freres Lumber Co. Inc. And, because the cost of living is lower, it’s not surprising that Oregon’s median wage is also DAN D. -
Fidelity® Nasdaq Composite Index® Fund
Fidelity® Nasdaq Composite Index® Fund Semi-Annual Report May 31, 2021 Contents Note to Shareholders 3 Investment Summary 4 Schedule of Investments 6 Financial Statements 85 Notes to Financial 89 Statements Shareholder Expense 97 Example Board Approval of 98 Investment Advisory Contracts and Management Fees Liquidity Risk 106 Management Program To view a fund’s proxy voting guidelines and proxy voting record for the 12-month period ended June 30, visit http://www.fidelity.com/proxyvotingresults or visit the Securities and Exchange Commission’s (SEC) web site at http://www.sec.gov. You may also call 1-800-544-8544 to request a free copy of the proxy voting guidelines. Nasdaq®, OMX®, NASDAQ OMX®, Nasdaq Composite®, and The Nasdaq Stock Market®, Inc. are registered trademarks of The NASDAQ OMXGroup, Inc. (which with its Affiliates are the Corporations) and are licensed for use by Fidelity. The product has not been passed on by the Corporations as to its legality or suitability. The product is not issued, endorsed or sold by the Corporations. The Corporations make no warranties and bear no liability with respect to shares of the product. Standard & Poor’s, S&P and S&P 500 are registered service marks of The McGraw-Hill Companies, Inc. and have been licensed for use by Fidelity Distributors Corporation. Other third-party marks appearing herein are the property of their respective owners. All other marks appearing herein are registered or unregistered trademarks or service marks of FMR LLC or an affiliated company. © 2021 FMR LLC. All rights reserved. This report and the financial statements contained herein are submitted for the general information of the shareholders of the Fund. -
Fidelity® Nasdaq Composite Index® Fund
Quarterly Holdings Report for Fidelity® Nasdaq Composite Index® Fund February 28, 2021 EIF-QTLY-0421 1.814098.116 Schedule of Investments February 28, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.7% Shares Value COMMUNICATION SERVICES – 16.7% Diversified Telecommunication Services – 0.2% Alaska Communication Systems Group, Inc. 34,501 $ 112,818 Anterix, Inc. (a) 7,844 331,252 ATN International, Inc. 7,220 351,470 Bandwidth, Inc. (a) (b) 12,082 1,913,306 Cogent Communications Group, Inc. (b) 25,499 1,526,115 Consolidated Communications Holdings, Inc. (a) 21,768 114,500 Iridium Communications, Inc. (a) 77,117 2,954,352 Liberty Global PLC: Class A (a) 112,326 2,766,028 Class B (a) 327 7,521 Class C (a) 204,417 4,967,333 Liberty Latin America Ltd.: Class A (a) 17,405 190,933 Class C (a) 105,781 1,159,360 ORBCOMM, Inc. (a) 54,925 419,078 Radius Global Infrastructure, Inc. (a) (b) 37,222 460,808 Sify Technologies Ltd. sponsored ADR (a) (b) 7,275 22,916 Vonage Holdings Corp. (a) 142,421 1,882,806 19,180,596 Entertainment – 2.5% Activision Blizzard, Inc. 429,734 41,086,868 Bilibili, Inc. ADR (a) (b) 99,200 12,496,224 Blue Hat Interactive Entertainment Technology (a) (b) 13,117 16,659 Chicken Soup For The Soul Entertainment, Inc. (a) 2,009 51,370 Cinedigm Corp. (a) 73,305 102,627 CuriosityStream, Inc. Class A (a) 24,573 426,833 DouYu International Holdings Ltd. ADR (a) 82,330 1,180,612 Electronic Arts, Inc. -
Nasdaq Capital Market Friday, December 28, 2018 5:32 PM
Nasdaq Capital Market Friday, December 28, 2018 5:32 PM Name Symbol Close 3PEA International TPNL 3.35 Abeona Therapeutics ABEO 7.02 Ability ABIL 2.02 Abraxas Petroleum AXAS 1.08 Acasti Pharma ACST 0.73 Accelerate Diagnostics AXDX 11.78 Acer Therapeutics ACER 18.25 Achieve Life Sciences ACHV 1.2 ACNB ACNB 38.73 Adamis Pharmaceuticals ADMP 2.1 Adesto Technologies IOTS 4.3 ADial Pharmaceuticals ADIL 5.55 ADMA Biologics ADMA 2.23 ADOMANI ADOM 0.25 Aehr Test Systems AEHR 1.44 Aerpio Pharmaceuticals ARPO 1.71 AEterna Zentaris AEZS 2.97 Aethlon Medical AEMD 1.52 Agenus AGEN 2.39 AGM Group Holdings AGMH 28.05 Airgain AIRG 10.04 AirMedia Group ADR AMCN 0.24 Air T AIRT 24.03 Akari Therapeutics ADR AKTX 1.63 Akers Biosciences AKER 1.27 Akoustis Technologies AKTS 4.79 Alberton Acquisition Cl A ALAC 9.8 Alberton Acquisition WT ALACW 0.12 Albireo Pharma ALBO 23.18 Aldeyra Therapeutics ALDX 8 Alithya Group Cl A ALYA 2.55 Alkaline Water WTER 3.24 Allegro Merger Rt ALGRR 0.3 Alliance MMA AMMA 0.17 Allied Healthcare Products AHPI 1.89 Alliqua BioMedical ALQA 2 Alta Mesa Resources AMR 1 Alta Mesa Resources WT AMRWW 0.08 Altus Midstream ALTM 7.75 AMCI Acquisition AMCIU 9.95 American Electric Technologies AETI 0.89 Ameri Holdings AMRH 0.17 Ameri Holdings WT AMRHW 0.03 Ames National ATLO 25.72 Anavex Life Sciences AVXL 1.52 Anixa Biosciences ANIX 4 Antares Pharma ATRS 2.63 Apollo Medical Holdings AMEH 20.73 Appliance Recycling Centers of ARCI 0.5 America Applied DNA Sciences APDN 0.38 Applied DNA Sciences WT APDNW ..